Browse by Audience
MEMBER

Update Your Profile
Special Interest Groups (SIG)
Member Spotlights
IASP Connect
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Pain Researcher
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Curricula
Graduate Opportunities
Treatment and Education Resources
Events

PATIENT & CAREGIVER

Resources for Living with Pain
Topic Pages
Free Videos
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner
Make a Donation

I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / Randomized open-label trial of intravenous brivaracetam versus lorazepam for acute treatment of increased seizure activity.

< BACK TO ARCHIVE


2020 May 14


Epilepsy Behav


http://www.ncbi.nlm.nih.gov/pubmed/32417382?dopt=Abstract


109

Randomized open-label trial of intravenous brivaracetam versus lorazepam for acute treatment of increased seizure activity.

Authors

Randomized open-label trial of intravenous brivaracetam versus lorazepam for acute treatment of increased seizure activity.
Szaflarski JP, Sadek A, Greve B, Williams P, Varner JA, Moseley BD
Epilepsy Behav. 2020 May 14; 109:107127.
PMID: 32417382.

Abstract

The objective of the present trial was to assess efficacy and safety of intravenous (IV) brivaracetam (BRV) vs. lorazepam (LZP) in patients with epilepsy undergoing evaluation in an epilepsy monitoring unit (EMU) who experienced seizures requiring acute treatment.
Read This Paper